Equities

OssDsign AB

OssDsign AB

Actions
  • Price (SEK)6.11
  • Today's Change0.11 / 1.83%
  • Shares traded173.12k
  • 1 Year change-3.32%
  • Beta0.7813
Data delayed at least 15 minutes, as of Nov 08 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OssDsign AB, formerly known as Oss-Q AB is a Sweden-based orthopedic medical device company. It aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The Company uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The Company's customers include neurosurgeons, craniofacial and maxillofacial surgeons.

  • Revenue in SEK (TTM)123.46m
  • Net income in SEK-113.80m
  • Incorporated2011
  • Employees27.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ortoma AB47.46m-29.81m327.99m7.00--1.99--6.91-0.7638-0.76381.264.650.24971.848.686,779,500.00-15.68-10.45-17.11-11.6469.05339.86-62.81-175.523.39--0.00-------38.87--14.14--
Acarix AB6.26m-70.95m338.27m9.00--4.56--54.06-0.1168-0.11680.00950.06970.08940.11722.47---101.38-66.93-123.43-77.1288.2779.42-1,133.87-1,483.685.21-328.980.00--7.2043.55-1.11------
ContextVision AB132.39m25.69m380.18m41.0014.804.2311.042.870.33760.33761.741.181.212.334.813,365,111.0023.3929.3930.6743.2797.3998.5819.4027.153.99--0.0304--12.197.78-1.77---35.88--
BrainCool AB (publ)37.48m-57.58m430.26m20.00--2.80--11.48-0.2635-0.26350.16950.60710.23782.013.761,561,500.00-36.54-47.14-39.83-70.16-32.65-149.77-153.65-391.453.64-5.860.00--32.0678.35-34.34---11.63--
Nexstim Oyj91.83m-9.66m431.49m39.00--19.92--4.70-0.1223-0.12231.190.27610.81960.22235.28214,040.30-8.62-26.77-14.02-43.9097.2492.11-10.52-38.381.24-5.510.7716---23.9422.08-201.58--19.51--
Integrum AB102.18m-2.52m440.79m36.00--2.45581.564.31-0.1244-0.12445.299.580.57060.56663.592,620,068.00-1.41-1.71-1.55-1.9887.2583.87-2.47-2.875.54-0.66360.0325--40.1935.91124.92--127.10--
SyntheticMR AB (publ)81.53m4.72m452.32m43.0095.683.9939.865.550.11340.11341.962.720.6049--1.532,203,514.003.507.194.248.8570.2769.705.799.08--18.000.006621.5030.6713.0570.34-7.3327.30--
Bioretec Oy47.27m-40.94m462.21m43.00--6.16--9.78-0.1752-0.17520.20240.3180.41041.233.75110,166.80-35.54-66.83-40.92-97.1969.9770.97-86.61-133.494.04--0.0696--32.7819.77-54.02------
Modulight Oyj39.99m-137.42m494.18m79.00--0.8201--12.36-0.2844-0.28440.08361.220.0516-0.31111.9449,271.43-17.72-8.39-18.97-9.10123.49114.69-343.58-56.814.50--0.0965---12.48-8.20-38.69--63.60--
OssDsign AB123.46m-113.80m596.70m27.00--2.65--4.83-1.40-1.401.432.300.43112.506.802,572,083.00-39.74-37.92-43.39-43.5683.9468.10-92.18-203.065.92-21.650.0114--96.8453.26-31.30---56.16--
Gentian Diagnostics ASA144.51m2.18m621.91m58.00324.803.9255.744.300.12620.12629.3510.470.77921.698.402,533,190.001.18-10.761.33-11.8651.6941.461.51-26.995.01--0.0394--32.9827.6354.92---4.92--
Omda AS410.47m89.02m637.39m295.007.1311.124.241.554.354.3520.602.790.5886238.3610.381,434,162.0013.80-4.9218.03-6.3792.8990.2223.45-9.831.142.560.8946--12.3019.83179.30---3.93--
Mentice AB280.75m-10.20m659.68m134.00--4.3239.892.35-0.3998-0.399810.955.970.90463.053.282,301,221.00-3.29-7.69-6.32-13.0785.3683.67-3.63-10.001.00--0.0382--25.5411.7490.81---10.83--
Senzime AB (publ)55.29m-131.46m723.08m52.00--2.68--13.08-1.09-1.090.45952.380.15331.574.91---36.44-35.69-39.12-38.0033.27-20.59-237.75-558.682.62--0.0739--154.7761.90-1.09---3.69--
ADDvise Group AB (publ)1.63bn114.40m825.70m643.0020.223.053.920.50770.59350.59358.383.930.5658.375.772,606,250.003.983.724.824.7742.0748.957.045.891.402.350.69690.940544.3038.6227.62--30.35--
Data as of Nov 08 2024. Currency figures normalised to OssDsign AB's reporting currency: Swedish Krona SEK

Institutional shareholders

9.31%Per cent of shares held by top holders
HolderShares% Held
East Capital Financial Services ABas of 10 Jul 20243.09m3.17%
Amundi Asset Management SA (Investment Management)as of 30 Aug 20242.80m2.87%
Carnegie Fonder ABas of 30 Sep 20241.98m2.03%
Schroder Investment Management Ltd.as of 31 Dec 2023600.19k0.62%
Wahlstedt & Partners ABas of 30 Sep 2024577.46k0.59%
FCG Fonder ABas of 30 Sep 202420.99k0.02%
Soci�t� G�n�rale Gestion SAas of 30 Aug 202416.94k0.02%
More ▼
Data from 30 Jun 2024 - 06 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.